Oppenheimer recommends buying Agilysys shares on weakness, durable growth expected
Oppenheimer analysts adjusted their outlook on Agilysys Inc (NASDAQ:AGYS), reducing the price target on the company's stock ...
Oppenheimer lifts Tarsus stock target, impressed by execution and ocular rosacea potential
Oppenheimer updated its outlook on Tarsus Pharmaceuticals (NASDAQ:TARS), a $1.8 billion market cap biotechnology company, ...